A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest
Launched by BAYER · May 20, 2021
Trial Information
Current as of May 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age from 18 to 35 y.o.
- • Indications for administration of estradiol valerate/ dienogest for the purpose of oral contraception.
- • Patients who did not take estradiol valerate/ dienogest for at least one month before enrollment into the study.
- • Signed informed consent to participate in the study
- • Exclusion criteria
- • Participation in an investigational program with interventions outside of routine clinical practice.
- • Contraindications to estradiol valerate/ dienogest according to the local market authorization.
- • Any medical and non-medical reasons that according to the physician's judgment may prevent patient's participation in the non-interventional study.
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials